Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-03-09Clinical Trial Update: The Effect of Nitric Oxide on Spatial Working Memory in Patients With Schizophrenia - Pilot Study [Phase 1]
Phase 1 pilot trial evaluating the effect of nitric oxide on spatial working memory in patients with schizophrenia.
-
FDA approval · 2016-03-08FDA Approved: QUETIAPINE FUMARATE — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved Quetiapine Fumarate as a generic tablet under Original Application (ANDA 202674) for Unichem Pharmaceuticals (USA), Inc.
-
CLINICAL_TRIALS trial_result · 2016-03-08Clinical Trial Update: Repetitive Transcranial Magnetic Stimulation (rTMS) as an add-on Treatment for Resistant Obsessive-compulsive Symptoms in Patients With Schizophrenia [NA]
A clinical trial update announcing completion of a study evaluating repetitive transcranial magnetic stimulation as an add-on treatment for …
-
CLINICAL_TRIALS trial_result · 2016-03-07Clinical Trial Update: Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective [Phase 1]
Clinical trial update indicating completion of a Phase 1 multiple ascending dose study evaluating safety, tolerability, and pharmacokinetics…
-
CLINICAL_TRIALS trial_result · 2016-03-04Clinical Trial Update: Efficacy of Pimozide Augmentation for Clozapine Partial Response [Phase 2]
Phase 2 trial evaluating whether adding pimozide to clozapine improves outcomes in schizophrenia patients with partial response. The results…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-03-03Clinical Trial Update: Efficacy Study of GAÏA Program Cognitive Remediation of Facial Affects Processing in Schizophrenia [NA]
A completed efficacy study of the GAÏA cognitive remediation program for facial affect processing in schizophrenia. The snippet does not pro…
-
FDA approval · 2016-03-01FDA Approved: RISPERIDONE — Supplemental Application (Janssen Pharmaceutical, Inc.)
FDA approved a supplemental application for risperidone submitted by Janssen Pharmaceutical, Inc.
-
FDA approval · 2016-03-01FDA Approved: RISPERDAL M-TAB — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Risperdal M-Tab (risperidone) from Janssen Pharmaceuticals.
-
FDA approval · 2016-03-01FDA Approved: RISPERDAL — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for Risperdal (risperidone) by Janssen Pharmaceuticals, Inc.
-
FDA approval · 2016-03-01FDA Approved: INVEGA SUSTENNA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for INVEGA SUSTENNA (paliperidone palmitate) filed by Janssen Pharmaceuticals.
-
FDA approval · 2016-03-01FDA Approved: INVEGA HAFYERA — Supplemental Application (Janssen Pharmaceuticals, Inc)
The FDA approved a supplemental application for INVEGA HAFYERA (paliperidone palmitate) from Janssen Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2016-03-01Clinical Trial Update: A Randomized, Double-blind, Comparison of the Efficacy and Safety of Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride in the Treatment of Schizophrenia [Phase 4]
A Phase 4 randomized, double-blind trial comparing amisulpride alone to a low-dose amisulpride plus sulpiride regimen in schizophrenia was t…
-
CLINICAL_TRIALS trial_result · 2016-02-25Clinical Trial Update: The Significance of Deviation in Time From the 12-hour Standard Serum-clozapine Monitoring. [Phase 4]
This Phase 4 trial update analyzes the significance of deviations from the 12-hour serum clozapine monitoring schedule in patients with schi…
-
CLINICAL_TRIALS trial_result · 2016-02-24Clinical Trial Update: Oxytocin as Adjunctive Therapy for Schizophrenia [Phase 2]
A Phase 2 clinical trial evaluating oxytocin as adjunctive therapy for schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2016-02-22Clinical Trial Update: Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia [NA]
Completed clinical trial evaluating transcranial current stimulation for auditory hallucinations in schizophrenia; results were posted in 20…
-
CLINICAL_TRIALS trial_result · 2016-02-22Clinical Trial Update: Effects of Cognitive Remediation Therapy on Schizophrenia Patients Through Functional Magnetic Resonance Imaging [NA]
A completed trial evaluating cognitive remediation therapy in schizophrenia, using functional MRI to assess brain changes and cognitive outc…
-
CLINICAL_TRIALS trial_result · 2016-02-19Clinical Trial Update: Effectiveness of Adherence Therapy for Schizophrenia [Phase 1, Phase 2]
A completed Phase 1/Phase 2 trial from The Hong Kong Polytechnic University evaluating the effectiveness of adherence therapy for schizophre…
-
CLINICAL_TRIALS trial_result · 2016-02-19Clinical Trial Update: Guideline vs Usual Treatment in Schizophrenic Adolescents [NA]
Completed clinical trial comparing guideline-based treatment to usual care in adolescents with schizophrenia.
-
FDA approval · 2016-02-18FDA Approved: VERSACLOZ — Supplemental Application (TruPharma LLC)
The FDA approved a supplemental application for Versacloz (clozapine) submitted by TruPharma LLC.
-
CLINICAL_TRIALS trial_result · 2016-02-12Clinical Trial Update: Role of Nintendo Wii in Improving Negative Symptoms and Quality of Life in Chronic Schizophrenia [NA]
The clinical trial testing whether a Nintendo Wii-based intervention can improve negative symptoms and quality of life in schizophrenia has …
-
CLINICAL_TRIALS trial_result · 2016-02-09Clinical Trial Update: The Effect of Plasma Osmolality on Brain Glutamate [Phase 1]
Phase 1 trial investigating the effect of plasma osmolality on brain glutamate levels in schizophrenia; study completed.
-
CLINICAL_TRIALS withdrawal · 2016-02-09Clinical Trial Update: Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia [Phase 2]
Phase 2 clinical trial of Org 24448 (an ampakine) for cognitive deficits in schizophrenia has been withdrawn.
-
CLINICAL_TRIALS research · 2016-02-09Clinical Trial Update: Remote Monitoring and Support for Patients With Schizophrenia, Schizoaffective or Bipolar Disorder on Adherence [NA]
Clinical trial update examining remote monitoring and support to improve medication adherence in patients with schizophrenia, schizoaffectiv…
-
CLINICAL_TRIALS trial_result · 2016-02-08Clinical Trial Update: Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults [Phase 2]
A Phase 2 clinical trial evaluating a cognitive adaptive e-treatment for adults with schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2016-02-08Clinical Trial Update: Sodium Oxybate in Schizophrenia With Insomnia [Phase 2]
Phase 2 clinical trial update of sodium oxybate in schizophrenia with insomnia; the study has completed and results were posted in February …